

ABSTRACT OF THE DISCLOSURE

The invention provides a combination, comprising an allosteric alkyne
5 inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with
celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a
pharmaceutically acceptable salt thereof. This invention also provides a method of
treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-
2, comprising administering to a patient suffering from such a disease the
10 invention combination comprising an allosteric alkyne inhibitor of MMP-13, or a
pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically
acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt
thereof. This invention also provides a pharmaceutical composition, comprising
the invention combination comprising an allosteric alkyne inhibitor of MMP-13,
15 or a pharmaceutically acceptable salt thereof, with celecoxib, or a
pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically
acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or
excipient. The invention combinations may also be further combined with other
pharmaceutical agents depending on the disease being treated.